Cargando…

Immune Checkpoint Inhibitors in Advanced NSCLC: [(18)F]FDG PET/CT as a Troubleshooter in Treatment Response

Introduction: The aim of this study was to investigate whether [(18)F]FDG PET/CT-derived semi-quantitative parameters can predict immunotherapy treatment response in non-small cell lung cancer (NSCLC) patients. Secondly, immune-related adverse events (irAEs) and lymphoid cell-rich organs activation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferrari, Cristina, Santo, Giulia, Merenda, Nunzio, Branca, Alessia, Mammucci, Paolo, Pizzutilo, Pamela, Gadaleta, Cosmo Damiano, Rubini, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471751/ https://www.ncbi.nlm.nih.gov/pubmed/34574022 http://dx.doi.org/10.3390/diagnostics11091681

Ejemplares similares

Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [(18)F]FDG PET/CT
por: Ferrari, Cristina, et al.
Publicado: (2021)

[(18)F]FDG PET/CT in head and neck squamous cell carcinoma: a head-to-head between visual point-scales and the added value of multi-modality imaging
por: Ferrari, Cristina, et al.
Publicado: (2023)

Comparison of the Diagnostic Value of MRI and Whole Body (18)F-FDG PET/CT in Diagnosis of Spondylodiscitis
por: Altini, Corinna, et al.
Publicado: (2020)

Pediatric Hodgkin Lymphoma: Predictive value of interim (18)F-FDG PET/CT in therapy response assessment
por: Ferrari, Cristina, et al.
Publicado: (2017)

Usefulness of (18)F-FDG PET/CT in Patients with Cardiac Implantable Electronic Device Suspected of Late Infection
por: Rubini, Giuseppe, et al.
Publicado: (2020)

[(18)F]Fluciclovine PET/CT Improves the Clinical Management of Early Recurrence Prostate Cancer Patients
por: Nappi, Anna Giulia, et al.
Publicado: (2022)

Diagnostic Value of Choline PET in the Preoperative Localization of Hyperfunctioning Parathyroid Gland(s): A Comprehensive Overview
por: Ferrari, Cristina, et al.
Publicado: (2021)

Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview
por: Ferrari, Cristina, et al.
Publicado: (2021)

Tumor glycolytic profiling through (18)F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC
por: Silva, Saulo Brito, et al.
Publicado: (2022)

Lesion-to-Liver SUVmax Ratio to Improve the Prognostic Value of the End of Treatment PET/CT in Diffuse Large B-Cell Lymphoma
por: Ferrari, Cristina, et al.
Publicado: (2022)

[F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients
por: Nappi, Antonio, et al.
Publicado: (2015)

Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation
por: Ranieri, Girolamo, et al.
Publicado: (2017)

The Day after Mass COVID-19 Vaccination: Higher Hypermetabolic Lymphadenopathy Detection on PET/CT and Impact on Oncologic Patients Management
por: Ferrari, Cristina, et al.
Publicado: (2021)

Hematogenous muscular metastasis of NSCLC in FDG-PET/CT
por: Satoh, Hiroaki, et al.
Publicado: (2015)

(18)F-FDG PET and DCE kinetic modeling and their correlations in primary NSCLC: first voxel-wise correlative analysis of human simultaneous [18F]FDG PET-MRI data
por: Besson, Florent L., et al.
Publicado: (2020)

[(18)F]fluciclovine vs. [(18)F]fluorocholine Positron Emission Tomography/Computed Tomography: A Head-to-Head Comparison for Early Detection of Biochemical Recurrence in Prostate Cancer Patients
por: Ferrari, Cristina, et al.
Publicado: (2022)

(18)F-FDG PET/CT Role in Staging of Gastric Carcinomas: Comparison with Conventional Contrast Enhancement Computed Tomography
por: Altini, Corinna, et al.
Publicado: (2015)

Impact of (18)F-FDG PET/CT, CT and EBUS/TBNA on preoperative mediastinal nodal staging of NSCLC
por: Al-Ibraheem, Akram, et al.
Publicado: (2021)

Differences between TNM classification and 2-[(18)F]FDG PET parameters of primary tumor in NSCLC patients
por: Cegla, Paulina, et al.
Publicado: (2021)

18-FDG PET in lung transplantation
por: Algieri, I, et al.
Publicado: (2015)

Myocarditis on (18)FDG-PET imaging
por: Chaaban, Nourhan, et al.
Publicado: (2022)

Intracranial Solitary Fibrous Tumor: A “New” Challenge for PET Radiopharmaceuticals
por: Sardaro, Angela, et al.
Publicado: (2022)

Clinical Relevance of [(18)F]Florbetaben and [(18)F]FDG PET/CT Imaging on the Management of Patients with Dementia
por: Librizzi, Damiano, et al.
Publicado: (2021)

PET probes beyond (18)F-FDG
por: Jiang, Lei, et al.
Publicado: (2014)

Feasibility of (18)FDG PET in the cardiac inflammation
por: Osiecki, Sebastian, et al.
Publicado: (2020)

Troubleshooting for F-18 Fluorocholine Synthesis: An Institutional Experience
por: Vatsa, Rakhee, et al.
Publicado: (2018)

Implications of False Negative and False Positive Diagnosis in Lymph Node Staging of NSCLC by Means of (18)F-FDG PET/CT
por: Li, Shaolei, et al.
Publicado: (2013)

Repeatability of [(18)F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients
por: Kolinger, Guilherme D., et al.
Publicado: (2019)

(18)F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival
por: Polverari, Giulia, et al.
Publicado: (2020)

Predictive Power of a Radiomic Signature Based on (18)F-FDG PET/CT Images for EGFR Mutational Status in NSCLC
por: Li, Xiaofeng, et al.
Publicado: (2019)

PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score
por: Dondi, Francesco, et al.
Publicado: (2023)

Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma
por: Amrane, Karim, et al.
Publicado: (2019)

Measurement Repeatability of (18)F-FDG PET/CT Versus (18)F-FDG PET/MRI in Solid Tumors of the Pelvis
por: Fraum, Tyler J., et al.
Publicado: (2019)

Heterogeneous Response to Immunotherapy in a Patient with Tonsillar Squamous Cell Carcinoma Assessed by (18)F-FDG PET/CT
por: Niccoli Asabella, Artor, et al.
Publicado: (2021)

18F-FDG PET/MRI and 18F-FDG PET/CT for the Management of Gynecological Malignancies: A Comprehensive Review of the Literature
por: Allahqoli, Leila, et al.
Publicado: (2023)

Prospective Analysis of (18)F-FDG PET/CT Predictive Value in Patients with Low Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy and Conservative Surgery
por: Niccoli-Asabella, Artor, et al.
Publicado: (2014)

Chemotherapy response evaluation in metastatic non-small cell lung carcinoma (NSCLC) with 18F- FDG PET/CT and CT scan
por: Fathinul, F, et al.
Publicado: (2014)

Impact of EBUS-TBNA in addition to [(18)F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC
por: Guberina, Maja, et al.
Publicado: (2021)

Metabolic patterns on [(18)F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment
por: Holzgreve, Adrien, et al.
Publicado: (2023)

Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [(18)F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
por: Lopci, Egesta
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lku2j9lpfhi2ui0t9uptli4jl8